Get started

Nyse

Lilly - Clean Chart StructureWe are analyzing the move starting from August 2025. So far, four out of five waves have been drawn. The structure of the fourth wave is an expanded flat (with measured moves): A = 134 -> five-wave move (impulse) B = 156 -> three-wave move C = 120 -> five-wave move (zigzag, internal impulses ≈60) The correction appears complete in both structure and proportions. Similar to the second wave, the fourth wave retraced 0.382 of the prior move. Even if price dips slightly, the main targets remain unchanged. Additionally, we seem to have caught the very start of the next move, and the fifth sub-wave should now begin. Key targets: 1,171 1,263 (aligns with the higher time frame) or somewhere within this range The upside potential from the current level is estimated at 14 - 22 %. --- Please subscribe and leave a comment! You’ll get new information faster than anyone else. ---
NYSE:LLYLong
by NotBoringTrading
Chevron (CVX) – Long Setup with Venezuela CatalystChevron NYSE:CVX is the only major U.S. oil company still operating in Venezuela, giving it a strategic advantage if there’s any stabilization or regime shift in the country’s oil sector. Additionally, Chevron is owed billions by Venezuela’s state oil company (PDVSA) — representing potential upside if debt negotiations or repayments are revived. This geopolitical angle adds a fundamental catalyst to an already strong technical setup. 📈 Technical Setup Bullish structure intact above the 200-week EMA Strong demand zone: $140–$150 Key resistance at $170 – a break and hold above this level could trigger a squeeze toward all-time highs 📊 Trade Plan Entry Zone: $140 – $150 Take Profit Targets: TP1: $190 – $200 TP2: $250 – $260 Stop Loss: Weekly close below $130
NYSE:CVXLong
by Richtv_official
IonQ (NASDAQ: IONQ) – Strong Reversal Structure Forming Within WIonQ is showing strong signs of recovery, holding firmly within the Fib golden zone and an overlapping weekly FVG that aligns with an OTE retracement, which previously broke market structure to the upside. This confluence zone has proven to be a solid base of support, and as long as price continues to respect this level, the bias remains bullish. From a swing perspective, our primary target zone sits around $136, completing a full bullish swing structure. Notably, recent fundamental analysis supports this outlook — with sources such as Yahoo Finance projecting long-term growth potential and even forecasting possible $1,000 price targets in extended market cycles. Technical View: - Weekly structure: bullish BOS confirmed - Price holding key FVG/OTE confluence - Next major liquidity targets: $84 → $136 Disclaimer: This breakdown is for educational purposes only and does not constitute financial advice. Always DYOR (Do Your Own Research) before making investment or trading decisions.
NYSE:IONQLong
by INSIDER_INTEL
2
Jabil - Downtrend BeginsThe move from early April 2025 - the fifth wave - is complete. The larger fifth wave from March 2020 is also complete. Ahead of us: corrective action. We may miss the exact local targets, as they are only starting to form, but preliminary levels are: Key targets (choose any): 206 -> 187 -> 180 -> 172 -> 153 -> 136 On a larger scale, the full fifth-wave structure should be corrected, potentially reaching the 136 area or even l ower . --- Please subscribe and leave a comment. You’ll get new information faster than anyone else. ---
NYSE:JBLShort
by NotBoringTrading
Chevron - Moving HigherWe’re evaluating the move from a purely technical perspective. What do we see? Three waves have already been completed, and not long ago the 4th corrective wave was finished. After that, a larger fifth wave to the upside began. This move did not start now - it began back in April 2025. There is still a chance of a deeper pullback toward the 125 area, but the probability is relatively low. In any case, such a correction would not affect the global targets. Local targets: 180 -> 209 -> 238 -> 256 Global targets: 237 -> 269 --- Please subscribe and leave a comment. You’ll get new information faster than anyone else. ---
NYSE:CVXLong
by NotBoringTrading
APPL Breakdown: BOS & CHoCH NASDAQ:AAPL On the H1 timeframe, the market structure has already produced a downside BOS, followed by a confirmed CHoCH. This clearly indicates that bullish momentum has ended and the market has shifted into a bearish trend. Price has rejected from a bearish Order Block and FVG zone on the upside, highlighting strong institutional selling pressure. As long as price remains below this resistance, selling pressure is expected to remain active. MACD also supports this analysis, with the MACD line below the signal line and the histogram in the negative zone, confirming momentum weakness and bearish continuation. Bias: As long as price stays below 274.00, sell continuation is expected. Current Price / Sell: 270.78 Stop Loss: 274.00 Targets: TP1: 265.50 TP2: 260.00 Disclaimer This chart is for educational purposes only and does not constitute financial advice. Trading involves high risk; always conduct your own research and use proper risk management.
NASDAQ:AAPLShort
by Markovic_VascoView
Trio-Tech (NYSE: TRT) Breaks to New Highs — $13+ Pre-MarketSince our last alert, Trio-Tech International (NYSE: TRT) has officially pushed to new highs, confirming that yesterday’s breakout was not a one-day move. Price action continues to show strong follow-through, signaling that momentum buyers remain firmly in control. This is exactly what we look for after a technical breakout: continuation, not hesitation. AMEX:TRT Breaks to New High Trio-Tech (NYSE: TRT) recently cleared its prior resistance and has now printed fresh highs, reinforcing the bullish structure on the chart. Breakouts that hold and expand are often indicative of an ongoing repricing phase rather than a short-term spike. Backed by rising demand in semiconductor testing—particularly from AI, industrial electronics, and high-performance computing, Trio-Tech International (NYSE: TRT) remains positioned as a mission-critical provider rather than a speculative concept. Trio-Tech International (NYSE: TRT) has seen its stock price climb +105.17% over the past 52 weeks, reflecting strong investor interest. Over the last 12 months, the company generated revenue of $42.19 million and net profits of $272,000, translating to earnings per share of $0.06. Gross profit reached $9.41 million, with a gross margin of 22.30%.  Technical Snapshot Breakout from falling wedge confirmed • New highs established • Momentum remains firmly bullish • Prior resistance now acting as support From a technical perspective, this is constructive price behavior.
AMEX:TRTLong
by DEXWireNews
Oracle - Seeking SymmetryLet’s examine the corrective impulsive move that began in September 2025. When breaking this movement down into waves and sub-waves, we can observe multiple waves that are roughly equal in size at both the beginning and the end of the structure, marked in red . If the wave count is correct, one final wave is still missing - its projected size is marked in blue . This becomes especially evident if we extend a flat correction from the last completed fifth wave and take into account that it typically retraces 50–60% of the prior wave. Under these assumptions, the structure aligns well. Additionally, when applying Fibonacci levels from the first impulsive wave, they converge with the projected completion area of the move. Conclusion: The move is targeting the 150 level. From that area, a new phase of price action is expected to begin. --- Please subscribe and leave a comment. You’ll get new information faster than anyone else. ---
NYSE:ORCLShort
by NotBoringTrading
Breaking: Novo Nordisk A/S (NVO) Set For 80% BreakoutShares in Novo Nordisk surged over 7% Tuesday premarket after the Wegovy maker secured approval of its GLP-1 pill — a world first. The U.S. Food and Drug Administration’s approval of Novo Nordisk’s GLP-1 pill gives the Danish pharmaceutical giant a head start over U.S. rival Eli Lilly The pill’s starting dose of 1.5 milligrams will be available in pharmacies and via select telehealth providers with savings offers for $149 per month in early January, the firm said. Cash-paying patients can access it for the same price via President Donald Trump’s direct-to-consumer website, TrumpRx, according to the deal Novo Nordisk struck with his administration last month. Drug pricing has been top of mind this year as the U.S. looks to reduce the costs paid by consumers. The approval caps a turbulent year for Novo, which has been marked by board drama, supply chain shortages, a bidding war against Pfizer, and criticisms over the execution of its U.S. strategy. Technically, NYSE:NVO stock is gearing for a 80% breakout as the asset is set to break above the symmetrical triangle pattern amidst the FDA approval news bid. About NVO Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
NYSE:NVOLong
by DEXWireNews
HII - High PotentialFrom early October 2011 to February 2018, Huntington Ingalls Industries was in a growth phase. This was followed by a prolonged correction lasting from February 2018 to February 2025. During this corrective phase, the price dropped by more than 50% and overlapped the sub-wave 1 , confirming the completion of the move. Since February 2025, Huntington Ingalls Industries has been showing an impulsive upward movement. Based on these factors, it can be assumed that the large waves 1 and 2 have already been completed, and the HII chart is now developing wave 3 . Summary: Significant upside potential remains in the long term. In the next idea, we will take a closer look at the current impulsive move. --- Please subscribe and leave a comment. You’ll get new information faster than anyone else. ---
NYSE:HIILong
by NotBoringTrading
Trio-Tech (NYSE: TRT) Jumps Nearly 22% Today Trio-Tech International (NYSE: TRT) shares are up 21% in Monday market trading session, The technical outlook still remains bullish as momentum is building. The stock recently broke out of a falling wedge pattern, signaling a potential surge toward $20 resistance despite broader market conditions. Shares of AMEX:TRT are in a position of extreme bullish momentum and the potential for further upside in the near term. Trio-Tech International (NYSE: TRT) has seen its stock price climb +63.47% over the past 52 weeks, reflecting strong investor interest. Over the last 12 months, the company generated revenue of $42.19 million and net profits of $272,000, translating to earnings per share of $0.06. Gross profit reached $9.41 million, with a gross margin of 22.30%. Operating and net profit margins remain modest at 0.18% and 0.64%, respectively, while return on equity (ROE) sits at 1.18% and return on invested capital (ROIC) at 0.13%, highlighting a stable but efficient capital deployment strategy. In recent news, announced that its Board of Directors has approved a 2-for-1 forward stock split of the Company’s outstanding common stock. The split will be effected through an amendment to the Company’s Articles of Incorporation. Each shareholder of record as of the close of trading on December 29, 2025 (the “Record Date”) will receive, after the close of trading on January 2, 2026, one additional share for every share held on the Record Date. About TRT Trio-Tech International, together with its subsidiaries, offers manufacturing, testing, and distribution services to the semiconductor industry in the United States, Singapore, Malaysia, Thailand, and China. It operates through Manufacturing, Testing, Distribution, and Real Estate segments.
AMEX:TRTLong
by DEXWireNews
CCL - Proceed with CautionAt the end of August 2025, CCL completed its upward move. Until the end of November, it formed a corrective wave A . Current Situation: Since late November, a full five-wave impulsive move upward has developed. If the first wave is correctly identified, a fast correction is likely next - around 50% of the move, targeting 28 . As this is wave B , after the correction, the upward move could continue toward 33 or slightly higher. --- Please subscribe and leave a comment. You’ll get new information faster than anyone else. ---
NYSE:CCLShort
by NotBoringTrading
BFLY — Butterfly Network Inc. | August 27, 2025.NYSE:BFLY #BFLY — Butterfly Network Inc. (NYSE:BFLY) | Healthcare | Medical Devices | USA | NYSE | August 27, 2025. Executive Summary Butterfly Network Inc. (NYSE: BFLY), an innovative medical device company specializing in portable ultrasound technology, exhibits strong insider conviction through a recent purchase by Chief Business Officer Steve Cashman. On August 25, 2025, Cashman acquired 50,000 shares of Class A common stock at an average price of $1.64 per share, totaling $81,953 in value. This transaction, disclosed via SEC Form 4 on August 27, 2025, increased his direct holdings to 2,324,474 shares, representing a significant vote of confidence in the company's trajectory amid a challenging market environment. Technical indicators on the daily chart suggest a potential reversal from a prolonged downtrend, with the stock trading at oversold levels and showing early signs of stabilization near $1.57. Q2 2025 financials reported record revenue of $23.4 million (up 9% YoY), with net losses narrowing by 59%, bolstered by cost efficiencies and AI-driven product enhancements. Recent news highlights include a new distribution agreement with Clipper Distributing for veterinary applications (August 25, 2025) and participation in an AI-assisted POCUS research project for tuberculosis detection in Sub-Saharan Africa (August 19, 2025), underscoring growth in both human and animal health sectors. Replicating Cashman's buy at approximately $1.64 presents a high probability of profitability, with estimated upside potential of 50-200% over the next 6-12 months, targeting $2.50-$5.00. This is supported by Zacks Rank #2 (Buy) and analyst projections of 124-127% upside. We recommend a speculative long position with tight risk controls, allocating 1-2% of portfolio capital, given the asymmetric reward in the medtech space. Company Profile Butterfly Network Inc. (BFLY) is a Burlington, Massachusetts-based healthcare technology firm revolutionizing medical imaging through its handheld, AI-enabled ultrasound devices. The flagship product, the Butterfly iQ+ probe, integrates semiconductor technology with cloud-based software to provide affordable, portable point-of-care ultrasound (POCUS) solutions for clinicians worldwide. The company operates in the medical devices sector, targeting applications in cardiology, emergency medicine, and now veterinary care, with a focus on democratizing access to diagnostic imaging in underserved markets. Key financial metrics as of August 27, 2025: • Market Capitalization: $395.24 million • Enterprise Value: $268.75 million (approx.) • Price-to-Sales (TTM): 4.52 • Price-to-Book (MRQ): 1.69 BFLY's business model emphasizes subscription-based software and AI integrations, with recent expansions into veterinary and global health initiatives driving revenue diversification. The company reported a cash position enabling continued R&D investment, though profitability remains elusive amid scaling efforts. Charts: • (1D) • (5D) Steve Cashman (Insider), Insider Trades: BFLY Ownership: SEC From 4: www.sec.gov Insider Activity Analysis Insider purchases, particularly by C-suite executives, often signal undervaluation and internal optimism about future catalysts. For BFLY, CBO Steve Cashman's August 25, 2025, acquisition of 50,000 shares at $1.64 per share is noteworthy, as it occurs near 52-week lows and follows a pattern of net insider buying. Post-transaction, Cashman's direct ownership stands at 2,324,474 shares, reflecting a substantial personal stake aligned with shareholders. Broader insider trends show mixed activity: While insiders sold approximately $1.6 million in stock over the past year, recent months have tilted toward buys, including this transaction. No other major executive purchases were reported in August 2025, but the absence of sales post-Q2 earnings suggests stabilizing sentiment. This aligns with historical data where clustered buys in medtech firms precede 20-50% rebounds within quarters, especially when tied to product launches or partnerships. Technical Analysis The daily chart for BFLY depicts a pronounced downtrend since peaking above $5.00 in early 2025, with the price eroding over 60% to current levels around $1.57 amid broader healthcare sector pressures. Price action forms a descending wedge pattern, characterized by lower highs and lows, trading below key simple moving averages (20-day SMA at $1.74, 50-day at $2.50, 200-day at $2.81), confirming bearish momentum. However, recent sessions exhibit green candles with modest volume spikes (e.g., 1.44M shares on August 27), hinting at accumulation. Key indicators bolster a high-probability reversal case: • Relative Strength Index (RSI, 14-period): At 49.65 on the primary chart (neutral) and 38.75 on the secondary (approaching oversold <30), signaling potential exhaustion without bearish divergence. • Volume Analysis: Average volume has risen 15% month-over-month, aligning with insider activity and news releases, suggesting institutional interest. • Support and Resistance: Immediate support at $1.50 (recent swing low) and $1.21 (52-week low). Resistance at $1.80 (near-term pivot), $2.50 (50-day SMA), and $3.00 (prior consolidation zone). • Chart Patterns: The wedge could resolve bullishly if price breaks above $1.80 on volume, targeting a measured move to $3.00+. Elliott Wave interpretation suggests completion of a five-wave decline, with the current level as a Wave 5 low, setting up for a corrective ABC rally. Overall , the setup offers a 70-80% chance of near-term profitability, as oversold conditions combined with insider buying often catalyze 50%+ gains in small-cap medtech stocks. Fundamental and News Analysis Fundamentally, BFLY delivered solid Q2 2025 results on August 1, 2025, with revenue reaching a record $23.4 million (9% YoY growth) and net loss reduced by 59% to an unspecified figure, driven by operational efficiencies and AI software adoption. Analysts project continued revenue expansion, with a Zacks Rank #2 (Buy) and consensus targets implying 124-127% upside. The company also announced a CFO transition effective August 1, 2025, to Heather Getz from Johnson & Johnson, bringing expertise in scaling medtech operations. Recent news reinforces momentum: ➖ August 25, 2025: Partnership with Clipper Distributing to expand Butterfly's ultrasound devices into veterinary markets, potentially unlocking new revenue streams in animal health. ➖ August 19, 2025: Joined a research project on AI-assisted POCUS for early tuberculosis detection in Sub-Saharan Africa, highlighting global health applications. ➖ August 1, 2025: Q2 earnings call emphasized Compass AI software launch for workflow efficiency, with management guiding for full-year revenue growth. Broader Context: The portable ultrasound market is forecasted to grow at 15% CAGR through 2030, benefiting BFLY's disruptive tech amid rising demand for point-of-care diagnostics. Social sentiment on X is positive around the Clipper partnership, with mentions of veterinary adoption and stock upside. No adverse events reported, though short interest remains elevated at 23.55% as of August 22, 2025. ➖➖➖ Investment Thesis and Forecast The insider buy at depressed valuations, coupled with technical bottoming and positive catalysts, positions BFLY for a rebound in the medtech sector. Replicating Cashman's entry at $1.64 yields the following scenario: Entry Price: $1.64 Potential Growth: 50-200% over 6-12 months, fueled by AI product launches and market expansions. Exit Targets: ➖ Conservative (Target 1): $2.50 (52% profit, +$0.86/share) – Exit at 50-day SMA or post-partnership revenue updates. ➖ Moderate (Target 2): $3.50 (113% profit, +$1.86/share) – Scale out 50% on RSI >70 or analyst upgrades. ➖ Aggressive (Target 3): $5.00 (205% profit, +$3.36/share) – Full exit on breakout above $4.00 or M&A speculation. This thesis assumes favorable macro conditions for healthcare tech; adjust for sector trends. Recommendation : Buy with conviction; target allocation 1-2% for high-conviction speculative basket. Disclaimer : This report is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.
NYSE:BFLYLong
by SergioRichi
1
AMRZ — Amrize Ltd = August 27, 2025.NYSE:AMRZ #AMRZ — Amrize Ltd (NYSE:AMRZ) | Basic Materials | Building Materials | Switzerland | NYSE | August 27, 2025. Executive Summary Amrize Ltd (NYSE: AMRZ), a Swiss-based building materials company focused on the North American market, demonstrates strong insider confidence through repeated purchases by Chief Technology Officer Roald Brouwer. In August 2025, Brouwer acquired a total of 5,000 shares across multiple transactions: 2,000 shares on August 27 at $51.88 per share (value $103,760), 1,000 shares on August 12 at $46.84 (value $46,840), 1,000 shares on August 11 at $48.08 (value $48,078), and 1,000 shares on August 8 at $46.25 (value $46,250). These buys, disclosed via SEC Form 4, increased his holdings to 5,000 shares, signaling optimism amid stable Q2 2025 results and strategic partnerships. Technical analysis reveals a bullish reversal setup on the daily chart, with the stock breaking out from consolidation near $46-48 to $51.96, supported by rising volume and neutral RSI, indicating high probability (75-85%) of continued upside. Q2 2025 financials showed stable revenue at $3.22 billion and net income of $428 million ($0.78 EPS), with cost-saving initiatives expected to boost margins from H2 2025. Key news includes a partnership with Meta announced on August 13, 2025, driving a 6.07% intraday gain, and analyst upgrades with targets implying 17-21% upside. Replicating Brouwer's average entry at ~$48.26 offers substantial reward potential of 20-50% over 3-6 months, targeting $58-$72. With a Zacks-style Buy rating and institutional backing, we view AMRZ as a high-conviction long in the materials sector, recommending 2-4% portfolio allocation for growth-oriented strategies. Company Profile Amrize Ltd (AMRZ) is a Zug, Switzerland-based company specializing in building materials, with operations exclusively focused on the North American market. Incorporated in 2023, Amrize earns revenue primarily from the sale of cement, aggregates, ready-mixed concrete, and related products, serving construction, infrastructure, and residential sectors. The firm positions itself as a key player in sustainable building solutions, leveraging advanced technology for efficient production and distribution. Key financial metrics as of August 27, 2025: • Market Capitalization: $28.72 billion • Enterprise Value: $36.98 billion (approx.) • Earnings Date: 11/5/2025 • Put Call Ration: 9.36 • Put Volume: 440.00 • Call Volume: 47.00 • Insider Ownership: 10.61% • Institutional Ownership: 31.55% Amrize's strategy emphasizes operational efficiency, with expected annual cost savings of $200-300 million starting in 2026 from ongoing initiatives. The company's strong balance sheet supports M&A and organic growth in a $200 billion North American building materials market. Charts: • (1D) • (30 Min) Roald Brouwer (Insider), Insider Trades: AMRZ Ownership: SEC From 4: www.sec.gov ➖➖➖ Insider Activity Analysis Insider buying serves as a robust indicator of undervaluation, especially when clustered and executed by technical leaders like the CTO, who have deep insights into innovation pipelines. For AMRZ, CTO Roald Brouwer's August 2025 purchases total 5,000 shares at an average price of $48.26, representing over $244,928 in value. This activity follows a pattern of executive accumulation, including President Jaime Hill's buys of 500 shares on August 22 at $49.59 and 4,000 shares on August 15 at $52.00. No significant sales were reported in Q3 2025, resulting in net insider buying of approximately $500,000 year-to-date. Brouwer's transactions, filed promptly via SEC Form 4, align with post-earnings stability and suggest confidence in near-term catalysts. Historically, such insider clusters in materials stocks correlate with 15-30% outperformance over six months, particularly in cyclical sectors like construction. ➖➖➖ Technical Analysis As a hedge fund trader, the daily chart for AMRZ presents a high-conviction bullish setup with an 80% probability of near-term gains, driven by a breakout from a multi-week consolidation base. Since bottoming at ~$46 in early August 2025, the stock has formed higher lows, culminating in a sharp volume-driven spike to $52.24 on August 27, closing at $51.96 (up 0.00% intraday but +12% month-to-date). This move breaches descending trendline resistance, confirmed by a bullish engulfing candle and 1.81 million share volume—50% above the 20-day average—indicating institutional accumulation. Key indicators affirm strength: • Moving Averages: Price above the 20-day SMA ($50.21) for the first time since July, with the 50-day SMA ($52.05) as next target; a golden cross (50-day over 200-day) is imminent if momentum holds. • Relative Strength Index (RSI, 14-period): At 56.61 (neutral-bullish), up from 40 in mid-August, with no overbought signals (>70) to suggest pullback risk. • Volume Analysis: OBV (On-Balance Volume) trending higher, supporting price advance; recent spikes align with insider buys and news. • Support and Resistance: Immediate support at $50.00 (psychological/20-day SMA) and $48.00 (prior breakout level). Resistance at $52.50 (recent high) and $55.00 (52-week high). • Chart Patterns: Ascending triangle breakout targets a measured move to $58 (adding pattern height to breakout point), with Fibonacci extensions from the August low pointing to $60 (161.8%). This configuration mirrors classic hedge fund plays in cyclical stocks, where insider-aligned breakouts yield 20-40% returns in 1-3 months amid sector tailwinds. ➖➖➖ Fundamental and News Analysis Fundamentally, AMRZ's Q2 2025 results (released August 6) underscore resilience: revenue held steady at $3.22 billion (vs. $3.243 billion YoY), with net income at $428 million ($0.78 EPS, down from $473 million but beating estimates by 5%). EBITDA margins improved to 21.5% via cost controls, positioning the company for $200-300 million in annual savings from H2 2025. Analysts project FY2025 EPS at $3.25 (forward P/E 16.0) and revenue growth of 5-7% in 2026, driven by North American infrastructure demand. Fresh news catalyzes upside: ➖ August 27, 2025: CTO Brouwer's 2,000-share buy reinforces post-earnings momentum. ➖ August 13, 2025: Strategic partnership with Meta for AI-optimized supply chain solutions, boosting stock 6.07% and highlighting tech integration in materials. ➖ August 6, 2025: Q2 earnings call emphasized "position of strength," with management guiding for margin expansion amid stable demand. Broader Context: U.S. infrastructure bill tailwinds and European supply chain shifts favor AMRZ's North American focus; analyst consensus (e.g., JP Morgan Price target at $60, Bernstein Price target at $62) implies 17-21% upside. Sentiment on X is bullish around the Meta deal, with posts noting potential for efficiency gains. Short interest low at 1.2%, reducing squeeze risk but affirming stability. ➖➖➖ Investment Thesis and Forecast Insider accumulation at undervalued levels, combined with technical breakout and earnings resilience, positions AMRZ for outperformance in materials. Entry Price : $51.96 Potential Growth : 11-38% over 3-6 months, leveraging infrastructure demand and tech partnerships. Exit Targets: ➖ Conservative (Target 1): $58.00 (11.62% profit) ➖ Moderate (Target 2): $65.00 (25.10% profit) ➖ Aggressive (Target 3): $72.00 (38.57% profit) Recommendation : Strong Buy; allocate 2-4% for cyclical exposure in diversified portfolios. Disclaimer: This report is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.
NYSE:AMRZLong
by SergioRichi
1
Coca-Cola (KO) Pullback Trade Aligns With Trend Strength!🔥 KO Playbook: Bullish Pullback Trap or Clean Rebound? 🥤📈 📌 Asset NYSE:KO — The Coca-Cola Company NYSE | Stock Market Profit Playbook Style: Swing Trade / Day Trade 🧠 Market Structure & Technical Thesis KO is currently showing a Bullish Pullback Setup after a healthy retracement into a Triangular Moving Average (TMA) zone, indicating potential mean-reversion and continuation strength. Key technical factors supporting the bullish bias: 📐 Price pulling back into TMA dynamic support 📉 Controlled retracement (no breakdown structure) 🧲 Liquidity resting below current price (ideal for layered entries) 📊 Context supports a buy-the-dip strategy, not a chase 🎯 Trade Plan — Thief Style (Layered Entry Method) 🕵️‍♂️ 🟢 Entry Strategy (Layering Method) This plan uses a multiple buy-limit layering strategy, also known as scale-in entries, to reduce average cost and manage volatility. Buy Limit Layers (Example): 🟢 70.00 🟢 69.50 🟢 69.00 👉 You may increase or adjust the number of limit layers based on your own risk management and execution style. 👉 Aggressive traders may also choose any price level entry, depending on confirmation. 🛑 Stop Loss (Risk Control) Thief SL Reference: 68.00 ⚠️ Note: Dear Ladies & Gentleman (Thief OG’s), I am not recommending you to use only my Stop Loss. Risk management is a personal choice — protect capital and trade responsibly. 🎯 Target / Exit Zone Primary Target: 73.00 🚨 Why this level matters: 🚓 “Police force” zone = Strong resistance area 📈 Price likely to be overbought near this zone Potential bull trap or profit-taking zone 👉 Kindly escape with profits if price reaches this level. ⚠️ Note: Dear Ladies & Gentleman (Thief OG’s), I am not recommending you to use only my Take Profit. Secure gains based on your own plan and comfort level. 🔍 Related Stocks to Watch (Correlation Insight) NASDAQ:PEP (PepsiCo Inc.) 🥤 👉 Strong sector correlation with KO. Bullish continuation in PEP often supports upside momentum in KO. AMEX:SPY (S&P 500 ETF) 📊 👉 Overall market strength matters. A bullish SPY environment increases follow-through probability for defensive stocks like KO. AMEX:XLP (Consumer Staples ETF) 🛒 👉 If XLP holds support or trends higher, KO usually benefits as a sector leader. 💡 FINAL THOUGHTS FROM YOUR TRADER This isn't a "set and forget" trade—it's an active, discipline-required play. The setup is clean, the technicals are aligned, but markets always have surprises. The margin of safety exists at these levels. But margin of safety ≠ guaranteed profit. Ever. Trade with conviction but manage risk like a pro. 🚀 📲 COMMUNITY APPRECIATION ✨ If you find value in my analysis, a 👍 and 🚀 boost is much appreciated — it helps me share more setups with the community! Happy Trading, Legends! 🚀💰 Chart your own path. The market rewards the prepared mind. 📊
NYSE:KO
by The-Thief
UNH Momentum Play ¦ MA Breakout + Structure Aligning for Bullish📈 UNH – UNITEDHEALTH GROUP INC. (NYSE) | Swing Trade Profit Playbook 🟢 🧠 Trade Thesis UNH is building momentum after clearing major pressure zones, and the chart structure hints at a bullish continuation once price powers above the breakout zone. Trend strength + MA positioning + momentum shift = a clean technical setup for swing traders. ⚡📊 🚀 Trade Plan (Bullish Breakout Play) 🔓 Breakout Entry Zone Primary Entry: Above $340.00 breakout level OR: Any price after a clean MA breakout confirmation 🔥📈 (Whichever comes first with volume is valid.) 🛑 Stop-Loss (Thief SL) SL: $300.00 💬 "Dear Ladies & Gentlemen (Thief OGs), I’m NOT recommending you copy my SL blindly. Entry & SL are your own choice — you make money, you take money at your own risk." 😎🔐 🎯 Take-Profit Zone Targeting $420.00 Why? Kijun Line acting as strong resistance Overbought conditions aligning Likely bull trap zone → perfect place to escape with profits 🏃‍♂️💨💰 💬 "Dear Ladies & Gentlemen (Thief OGs), TP is YOUR choice too — this is just my map. Manage your bag wisely." 😉 📌 Additional Market Notes Kijun MA = heavy ceiling. Price currently sitting in a trap-prone region, so trade execution timing matters. Breakout confirmation + sustained volume = stronger conviction. 🔍 Related Pairs / Correlations to Watch These assets often reflect broader US healthcare / insurance sector flows or large-cap market sentiment: NYSE:CVS – Healthcare services correlation; weakness/strength often echoes UNH structure. NYSE:HUM – Similar managed-care trend behavior; watch for sector rotation. NYSE:ELV – Moves in tandem with medical insurance majors; confirms sector direction. AMEX:SPY – Large-cap market momentum; strong SPY = supportive wind for UNH. AMEX:XLV – Healthcare ETF; acts as a sector-strength indicator. Key Point: If AMEX:XLV & AMEX:SPY are trending bullish while $HUM/ NYSE:ELV ** show momentum, UNH breakout continuation becomes more reliable. Sector rotation → strong confirmation tool. ⚖️📊 ✨ “If you find value in my analysis, a 👍 and 🚀 boost is much appreciated — it helps me share more setups with the community!” Disclaimer: This is thief-style trading strategy just for fun. 🕵️‍♂️💸 #UNH #SwingTrade #NYSE #BreakoutStrategy #ThiefStrategy #HealthcareStocks #StockMarket #TechnicalAnalysis #MomentumTrading #TrendTrading #Investing #TradingView
NYSE:UNHLong
by The-Thief
3